Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma. The first-generation protease inhibitors were a major advancement in the…
Gastrointestinal stromal tumors (GISTs) are rare cancers that belong to a group of cancers known as soft tissue sarcomas, which develop in supporting and connective tissues. GISTs account for…
This LaunchTrends report series will track the post-launch awareness, trial, and usage of Apremilast (Otezla) among rheumatologists for the treatment of Psoriatic Arthritis. Three waves of the…
Do Physicians Have High Hopes for LDL-Lowering Therapies in Cardiovascular Outcomes? As one of the most prevalent diseases in the major pharmaceutical markets, dyslipidemia represents a compelling…
Do Physicians Have High Hopes for LDL-Lowering Therapies in Cardiovascular Outcomes? As one of the most prevalent diseases in the major pharmaceutical markets, dyslipidemia represents a compelling…
Breakthrough therapy designation was introduced by the FDA in 2012 to expedite the drug development process for promising novel therapies for serious or life-threatening conditions. In 2013, of 28…
Major depressive disorder (MDD) continues to be a highly prevalent psychiatric disorder. Over 5 million drug-treated MDD patients in the United States fail to respond adequately to treatment with…
LaunchTrends: Tecfidera (US) is a four-wave syndicated report series that specifically tracks the introduction of Tecfidera, the third-to-market oral disease-modifying therapy (DMT), based on…
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma. The first-generation protease inhibitors were a major advancement in the…
Gastric cancer (GC) is a major public health burden in China and is the third leading cause of cancer-related deaths in the country. Although chemotherapy is the mainstay of treatment, prescribing…
The Chinese market for hepatocellular carcinoma (HCC) therapies represents an increasingly lucrative space for many pharmaceutical companies. Although the high prices demanded by targeted brands…
Opportunity Awaits Therapies Offering Improvements in Efficacy and Safety over Currently Available TNF-Alpha Inhibitors The availability of tumor necrosis factor alpha (TNF-α) inhibitors as…
Opportunity Awaits Therapies Offering Improvements in Efficacy and Safety over Currently Available TNF-Alpha Inhibitors The availability of tumor necrosis factor alpha (TNF-α) inhibitors as…
Significant Market Opportunity Awaits Therapies Offering Improvements in Efficacy over IV Belimumab for the Moderate to Severe Patient Segment Systemic lupus erythematosus (SLE) is a complex…
Significant Market Opportunity Awaits Therapies Offering Improvements in Efficacy over IV Belimumab for the Moderate to Severe Patient Segment Systemic lupus erythematosus (SLE) is a complex…